Abstract
The metabotropic glutamate receptor family comprises eight subtypes (mGlu1-8) of G-protein coupled receptors. mGlu receptors have a large extracellular domain which acts as recognition domain for the natural agonist glutamate. In contrast to the ionotropic glutamate receptors which mediate the fast excitatory neurotransmission, mGlu receptors have been shown to play a more modulatory role and have been proposed as alternative targets for pharmacological interventions. The potential use of mGluRs as drug targets for various nervous system pathologies such as anxiety, depression, schizophrenia, pain or Parkinsons disease has triggered an intense search for subtype selective modulators and resulted in the identification of numerous novel pharmacological agents capable to modulate the receptor activity through an interaction at an allosteric site located in the transmembrane domain. The present review presents the most recent developments in the identification and the characterization of allosteric modulators for the mGlu receptors.
Keywords: CPCCOEt, positive allosteric modulators, signal transduction, Fenobam, LY354740
Current Neuropharmacology
Title: Allosteric Modulators for mGlu Receptors
Volume: 5 Issue: 3
Author(s): F. Gasparini and W. Spooren
Affiliation:
Keywords: CPCCOEt, positive allosteric modulators, signal transduction, Fenobam, LY354740
Abstract: The metabotropic glutamate receptor family comprises eight subtypes (mGlu1-8) of G-protein coupled receptors. mGlu receptors have a large extracellular domain which acts as recognition domain for the natural agonist glutamate. In contrast to the ionotropic glutamate receptors which mediate the fast excitatory neurotransmission, mGlu receptors have been shown to play a more modulatory role and have been proposed as alternative targets for pharmacological interventions. The potential use of mGluRs as drug targets for various nervous system pathologies such as anxiety, depression, schizophrenia, pain or Parkinsons disease has triggered an intense search for subtype selective modulators and resulted in the identification of numerous novel pharmacological agents capable to modulate the receptor activity through an interaction at an allosteric site located in the transmembrane domain. The present review presents the most recent developments in the identification and the characterization of allosteric modulators for the mGlu receptors.
Export Options
About this article
Cite this article as:
Gasparini F. and Spooren W., Allosteric Modulators for mGlu Receptors, Current Neuropharmacology 2007; 5 (3) . https://dx.doi.org/10.2174/157015907781695900
DOI https://dx.doi.org/10.2174/157015907781695900 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Recent Advances in Potential Therapeutic Drugs for Cognitive Impairment in Schizophrenia
Current Psychiatry Reviews Advances in the Treatment of Neurodegenerative Disorders Employing Nanoparticles
Recent Patents on Drug Delivery & Formulation Exploring the Role of Monoamine Oxidase Activity in Aging and Alzheimer’s Disease
Current Pharmaceutical Design Music Therapy for Individuals with Dementia: Areas of Interventions and Research Perspectives
Current Alzheimer Research Mechanisms of Sleep-Wake Cycle Modulation
CNS & Neurological Disorders - Drug Targets Targeting TNF-Alpha to Elucidate and Ameliorate Neuroinflammation in Neurodegenerative Diseases
CNS & Neurological Disorders - Drug Targets Control by Substrate of the Cytochrome P450-Dependent Redox Machinery: Mechanistic Insights
Current Drug Metabolism Retromer Dysfunction and Neurodegenerative Disease
Current Genomics Protein-Protein Interface Analysis and Hot Spots Identification for Chemical Ligand Design
Current Pharmaceutical Design Neurophysiology of Sleep and Wakefulness: Basic Science and Clinical Implications
Current Neuropharmacology G Protein-Coupled Receptor Kinase 2 - a Feedback Regulator of Gq Pathway Signalling
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Protein Kinase A (PKA) - A Potential Target for Therapeutic Intervention of Dysfunctional Immune Cells
Current Drug Targets Hsp70s and J Proteins of Plasmodium Parasites Infecting Rodents and Primates: Structure, Function, Clinical Relevance, and Drug Targets
Current Pharmaceutical Design Pharmacological Treatment of Obstructive Sleep Apnea
Current Pharmaceutical Design Mesenchymal Stem Cells as a Source of Dopaminergic Neurons: A Potential Cell Based Therapy for Parkinson's Disease
Current Stem Cell Research & Therapy Astrocyte Pathology in Major Depressive Disorder: Insights from Human Postmortem Brain Tissue
Current Drug Targets Gastrointestinal Motility and Acute Toxicity of Pistagremic Acid Isolated from the Galls of Pistacia integerrima
Medicinal Chemistry Silymarin as a New Hepatoprotective Agent in Experimental Cholestasis: New Possibilities for an Ancient Medication
Current Medicinal Chemistry Mechanical Methods for Dry Particle Coating Processes and Their Applications in Drug Delivery and Development
Recent Patents on Drug Delivery & Formulation Electroporation Advances in Large Animals
Current Gene Therapy